financetom
Business
financetom
/
Business
/
J.M. Smucker forecasts annual profit below estimates as coffee inflation bites
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
J.M. Smucker forecasts annual profit below estimates as coffee inflation bites
Nov 25, 2025 9:01 AM

(Reuters) -J.M. Smucker on Tuesday forecast annual profit below analysts' estimates as a surge in coffee costs is expected to squeeze its margin, sending shares of the food maker down 3%.

The parent company of Folgers coffee, which imports green coffee mainly from Brazil and Vietnam, has been hit by U.S. President Donald Trump's steep duties on Brazilian imports this year.

U.S. consumer, hurt by still-high inflation, are also opting for cheaper private-label goods, hurting packaged food companies such as J.M. Smucker, Kraft Heinz ( KHC ) and Hormel Foods ( HRL ).

Meanwhile, a record U.S. government shutdown delayed federal pay and food-stamp benefits, rattling consumers ahead of the holiday season.

The company's overall prices rose 11 percentage points, while volumes decreased 6 percentage points for the quarter ended October 31.

Volumes in its U.S. coffee business, a major revenue generator, dragged net sales by 6 percentage points, while in pet food business they decreased by 8 percentage points.

Executives on a post-earnings call said the company was absorbing coffee tariffs and inflation without raising prices in its U.S. retail coffee portfolio this winter, which will result in additional costs of about $75 million.

Last week, the Trump administration removed 40% tariffs on imports of agricultural products from Brazil, including green coffee beans, but analysts say the benefit could come in the next year.

The Jif peanut butter maker's second-quarter net sales rose 2.6% to $2.33 billion from a year ago, slightly beating analysts' average estimate of $2.32 billion, according to data compiled by LSEG.

J.M. Smucker narrowed its annual net sales growth forecast to a range of 3.5% to 4.5%, from 3% to 5%. It also tightened its profit target to $8.75 to $9.25, from $8.50 to $9.50, the midpoint of which is below analysts' estimate of $9.08.

On an adjusted basis, it earned $2.10 per share, in line with analysts' estimates. 

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Gilead Sciences, US government settle patent case over HIV prevention drugs
Gilead Sciences, US government settle patent case over HIV prevention drugs
Jan 15, 2025
Jan 15 (Reuters) - Gilead Sciences ( GILD ) and the U.S. government have settled a billion-dollar patent dispute over Gilead's HIV prevention drugs Truvada and Descovy, according to a Wednesday filing in Delaware federal court. The settlement follows a victory for Gilead in a 2023 jury trial on the government's patent infringement allegations. Gilead General Counsel Deborah Telman said...
Automotive Properties REIT Declares January 2025 Distribution
Automotive Properties REIT Declares January 2025 Distribution
Jan 15, 2025
03:49 PM EST, 01/15/2025 (MT Newswires) -- Automotive Properties REIT (APR-UN.TO) Wednesday declared a distribution of $0.067 per REIT unit for the month of January, representing $0.804 per REIT unit on an annualized basis. This is consistent with December's cash distribution. Payment will be made on Feb. 18 to unitholders of record on Jan. 31. Price: 10.66, Change: +0.08, Percent...
Senators demand US trade chief Tai halt late talks on investor protections
Senators demand US trade chief Tai halt late talks on investor protections
Jan 15, 2025
WASHINGTON (Reuters) - A bipartisan group of U.S. senators on Wednesday called on U.S. Trade Representative Katherine Tai to stop secret negotiations with Mexico, Canada and Colombia that would weaken investor protections in some U.S. free trade deals during the Biden administration's final days. The letter, led by Senate Finance Committee Chairman Mike Crapo, a Republican, and the panel's top...
Gilead Sciences, US government settle patent case over HIV prevention drugs
Gilead Sciences, US government settle patent case over HIV prevention drugs
Jan 15, 2025
(Reuters) - Gilead Sciences and the U.S. government have settled a billion-dollar patent dispute over Gilead's HIV prevention drugs Truvada and Descovy, according to a Wednesday filing in Delaware federal court. The settlement follows a victory for Gilead in a 2023 jury trial on the government's patent infringement allegations. Gilead General Counsel Deborah Telman said in a statement that the...
Copyright 2023-2025 - www.financetom.com All Rights Reserved